Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
19 October, 2018 20:30 IST
Lupin receives nod for generic Nitrofurantoin capsules
Source: IRIS | 12 Jul, 2018, 12.39PM
Comments  |  Post Comment

Lupin's Nitrofurantoin Capsules USP (Macrocrystals), 50 mg and 100 mg is the generic version of Alvogen Malta Operations Macrodantin Capsules, 50 mg and 100 mg. It is specifically indicated for the treatment of urinary tract infections when due to susceptible strains of Escherichia coli, enterococci, Staphylococcus aureus, and certain susceptible strains of Klebsiella and Enterobacter species.



Lupin Limited   (Q,N,C,F)*

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Company Update
Lupin's Pithampur unit-3 inspected by USFDA - 19-Oct-2018 16:01
Surya Roshni bags order worth Rs 503.4 mn - 19-Oct-2018 11:22
Glenmark Pharma to present data on investigational treatment for Atopic Dermatitis - 19-Oct-2018 09:55
Zydus Cadila receives tentative approval for Colchicine tablets - 18-Oct-2018 16:21
Ramco Systems partners with Airbus Helicopters SAS - 18-Oct-2018 10:26
ABB secures order worth Rs 1.15 bn from Indian Railways - 18-Oct-2018 10:20
Zydus Cadila gets nod for Clobetasol propionate cream - 17-Oct-2018 15:19
Aurionpro Solutions to acquire majority stake in Singapore based SC Soft - 17-Oct-2018 13:26
Adani Group partners with Total to provide multi-energy offering - 17-Oct-2018 13:16
Sterlite Tech wins Rs 35 bn contract for Indian Navy's digital network - 16-Oct-2018 11:03
Lupin receives tentative approval for generic Lurasidone HCl tablets - 16-Oct-2018 09:42
more...
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer